Royalty Pharma (RPRX) Scheduled to Post Quarterly Earnings on Thursday

Royalty Pharma (NASDAQ:RPRX) will be issuing its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $0.96 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.12. The business had revenue of $736.00 million during the quarter, compared to analysts’ expectations of $702.90 million. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. On average, analysts expect Royalty Pharma to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Royalty Pharma Trading Up 0.3 %

NASDAQ RPRX opened at $28.49 on Tuesday. The company has a fifty day simple moving average of $29.31 and a two-hundred day simple moving average of $28.59. The stock has a market cap of $17.02 billion, a P/E ratio of 15.07 and a beta of 0.47. Royalty Pharma has a 12-month low of $25.92 and a 12-month high of $35.70. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.61.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be issued a $0.21 dividend. The ex-dividend date is Thursday, May 16th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.95%. Royalty Pharma’s dividend payout ratio is currently 44.44%.

Wall Street Analyst Weigh In

RPRX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. The Goldman Sachs Group reduced their target price on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Thursday, April 11th. Finally, Bank of America reduced their target price on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, April 12th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.